MSAC Secretariat publishes agenda for March 2023 MSAC meeting

MSAC

23 November 2022 - The MSAC Secretariat has published a list of applications scheduled to be considered by the MSAC on 30 -31 March 2023.

The agenda currently has 15 items. Applications of note include:

  • 1549 – PD-L1 immunohistochemistry testing for access to pembrolizumab in combination with chemotherapy for first line treatment of triple negative breast cancer
  • 1658.1 – Testing of tumour tissue to determine a positive homologous recombination deficiency status in women newly diagnosed with advanced (FIGO stage III-IV) high grade epithelial ovarian, fallopian tube or primary peritoneal cancer for access to PBS olaparib
  • 1703 – Detection of measurable residual disease in patients with acute lymphoblastic leukaemia
  • 1714 – National Blood Authority listing for susoctocog alfa for treatment of bleeding episodes with acquired haemophilia A
  • 1716 – Germline BRCA mutation test to detect BRCA1 or BRCA2 mutations in patients with HER2- negative high risk early breast cancer to determine eligibility for PBS-listed olaparib treatment
  • 1722 – Axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma
  • 1726 – Testing of tumour tissue to determine a positive homologous recombination deficiency status in women newly diagnosed with advanced (FIGO stage III-IV) high grade epithelial ovarian, fallopian tube or primary peritoneal cancer, for access to PBS niraparib

Read MSAC agenda

Michael Wonder

Posted by:

Michael Wonder